ModTect Software Uncovers Epitranscriptome Dysregulation Across Multiple Cancer Types

Researchers from the Cancer Science Institute of Singapore (CSI Singapore) have developed a software program - called ModTect - that can help reveal the relationships between RNA modifications and the development of diseases and disorders. Led by Professor Daniel Tenen and Dr Henry Yang, the scientists carried out their own novel pan-cancer study1 covering 33 different cancer types. This work is one of few studies demonstrating the association of mRNA modification with cancer development.

Rova-T Ineffective Against Small Cell Lung Cancer

Rovalpituzumab tesirine (Rova-T) is not effective against small-cell lung cancer (SCLC), four independent studies show. SCLC remains a difficult disease to treat, especially at the time of relapse. Currently, topotecan is among the most effective treatments, but it is not the most desirable and favored drug in the second-line setting because of its toxicity profile. Still, it has been difficult for new agents to “beat” this drug in the second-line setting.

What Are Antibody-drug Conjugates?

Antibody-drug conjugates (ADCs) are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs. Schematic structure of an antibody-drug conjugate (ADC). Credit: CC-BY Antibody-drug conjugates are complex molecules composed of an antibody linked to a biologically anticancer payload or drug.

Sulcal Stimulation With SEEG Implants Could Restore Feeling In Fingertips

A minimally invasive electrode brain implant evoked the sense of touch in a first-in-human study from The Feinstein Institutes for Medical Research. The work1 could potentially help millions of people who live with paralysis and neuropathy. From buttoning our shirts to holding a loved one’s hand, our sense of touch may be taken for granted until we lose it. These results show the ability to generate that sensation, even after it is lost, which may lead us to a clinical option in the future,

What Is Gemtuzumab Ozogamicin?

Gemtuzumab ozogamicin (brand name Mylotarg), is an antibody-drug conjugate used to treat acute myeloid leukemia. Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of stem cells. Mylotarg Side Effects The most common grade 3 and higher adverse reactions that occurred during Induction 1 and Intensification 2 in ≥ 5% of people who received gemtuzumab ozogamicin were infection, febrile neutropenia, decreased appetite, hyperglycemia, mucositis, hypoxia, hemorrhage, increased transaminase, diarrhea, nausea, and hypotension.

Short Daytime Naps Ineffective Against Sleep Deprivation

A nap during the day won’t give you relief from a sleepless night, according to a study from Michigan State University’s Sleep and Learning Lab1. We are interested in understanding cognitive deficits associated with sleep deprivation. In this study, we wanted to know if a short nap during the deprivation period would mitigate these deficits. We found that short naps of 30 or 60 minutes did not show any measurable effects,

Bcl-2 Regulator Protein

B-cell-lymphoma-2 (Bcl-2) is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis. It was the first apoptosis regulator identified in any organism1. Bcl-2 is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. Orthologs (such as Bcl2 in mice) have been identified2 in numerous mammals for which complete genome data are available.

LSL60101 Reduces Cognitive Deficit In Neurodegeneration

The compound LSL60101 improved cognitive deficit and biomarkers related to Alzheimer’s disease in studies carried out with mice. The work is described in a paper1 detailing the synthesis of a new family of compounds with high affinity and selectivity for imidazoline I2 receptors, altered in the brain of patients with Alzheimer’s. The synthesis pathway of compounds is efficient and affordable. It would allow different structural modifications to access a range of compounds of pharmaceutical interest.